InvestSMART

Raptor Metals Ltd (ASX: RAP) - Announcements

- Current share price for RAP : $0.017

ASX company news and announcements for Raptor Metals Ltd (RAP) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Raptor Metals Ltd (RAP) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Raptor Metals Ltd (RAP), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Raptor Metals Ltd (RAP)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$7 Correction to ASX announcement 3 Aug 2022 4:58PM $0.180 $0.017 fallen by 90.56%
$7 Entry into amended and restated Scheme Implementation Deed 3 Aug 2022 10:43AM $0.123 $0.017 fallen by 86.12%
$7 Investor Conference Call Notification 2 Aug 2022 5:37PM $0.120 $0.017 fallen by 85.83%
$7 Quarterly Activities Report and Appendix 4C 27 Jul 2022 9:22AM $0.115 $0.017 fallen by 85.22%
$7 Quarterly Results and Investor Conference Call Notification 25 Jul 2022 9:16AM $0.120 $0.017 fallen by 85.83%
$7 Study shows efficacy of ResAppDx use with masks 22 Jul 2022 9:20AM $0.125 $0.017 fallen by 86.40%
$7 Dispatch of Scheme Booklet 20 Jul 2022 4:35PM $0.135 $0.017 fallen by 87.41%
$7 Clarification - Scheme Booklet registered with ASIC 20 Jul 2022 4:27PM $0.135 $0.017 fallen by 87.41%
$7 Scheme Update - ACCC condition precedent satisfied 18 Jul 2022 12:22PM $0.135 $0.017 fallen by 87.41%
$7 Scheme Booklet registered with ASIC 18 Jul 2022 11:52AM $0.135 $0.017 fallen by 87.41%
$7 Results of First Court Hearing 15 Jul 2022 5:14PM $0.135 $0.017 fallen by 87.41%
$7 Medgate Licence Agreement Clarification Announcement 11 Jul 2022 9:10AM $0.130 $0.017 fallen by 86.92%
$7 Medgate extends licence agreement and plans to expand use 7 Jul 2022 9:06AM $0.130 $0.017 fallen by 86.92%
$7 ResApp receives FDA 510(k) clearance for SleepCheckRx 6 Jul 2022 9:26AM $0.135 $0.017 fallen by 87.41%
$7 Cough detection patent granted in Australia and Japan 5 Jul 2022 9:00AM $0.130 $0.017 fallen by 86.92%
$7 Scheme Update 30 Jun 2022 2:37PM $0.130 $0.017 fallen by 86.92%
$7 ResApp to present at Gold Coast Investment Showcase 23 Jun 2022 9:40AM $0.120 $0.017 fallen by 85.83%
$7 Results from Data Confirmation Study 21 Jun 2022 9:49AM $0.175 $0.017 fallen by 90.29%
$7 Trading Halt 20 Jun 2022 9:46AM $0.175 $0.017 fallen by 90.29%
$7 Investor Webinar 17 Jun 2022 8:52AM $0.170 $0.017 fallen by 90%
$7 Notification of cessation of securities - RAP 16 Jun 2022 6:30PM $0.170 $0.017 fallen by 90%
$7 Application for quotation of securities - RAP 16 Jun 2022 4:37PM $0.170 $0.017 fallen by 90%
$7 Notification of cessation of securities - RAP 14 Jun 2022 6:44PM $0.165 $0.017 fallen by 89.70%
$7 Reinstatement to Official Quotation 14 Jun 2022 12:34PM $0.165 $0.017 fallen by 89.70%
$7 Increased Scheme Consideration from Pfizer 14 Jun 2022 12:34PM $0.165 $0.017 fallen by 89.70%

76 - 100 of 581 results

Page 4 of 24

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.